Eli Lilly CEO Dave Ricks told CNBC that one-third of new GLP-1 pill patients are taking Foundayo as the company ramps up production to compete with rival Novo Nordisk. Lilly broke ground on a $6.5 billion manufacturing facility in Houston expected to be operational by 2030, part of over $50 billion in manufacturing investments since 2020. Foundayo, which launched in April, generated $98 million in sales in its first quarter on the market.